Everolimus

Manufactured by InvivoGen

Sourced in France

Everolimus is a macrolide compound that functions as an immunosuppressant and antiproliferative agent. It acts by inhibiting the mammalian target of rapamycin (mTOR) pathway, which regulates cell growth, proliferation, and survival.

Automatically generated - may contain errors

Lab products found in correlation

Bafilomycin a1, by InvivoGen (2 mentions) Marizomib, by Merck Group (1 mentions) Chloroquine, by Merck Group (1 mentions) Boc lstr amc, by Bachem (1 mentions) Ac nlpnld amc, by Bachem (1 mentions) Verteporfin, by Merck Group (1 mentions) Suc llvy amc, by Bachem (1 mentions) Rapamycin, by InvivoGen (1 mentions) Carbamazepine, by Bio-Techne (1 mentions) Goat anti mouse igg1 af488, by Thermo Fisher Scientific (1 mentions) Dnase type 1, by Worthington (1 mentions) Anti human lc3 4e12, by MBL Life Science (1 mentions) Dispase 2, by Roche (1 mentions) Collagenase d, by Roche (1 mentions)

2 protocols using everolimus

Proteasome and Autophagy Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Ac-nLPnLD-amc, Boc-LSTR-amc and Suc-LLVY-amc peptides were purchased from Bachem AG (Bubendorf, CHE). Marizomib, chloroquine and verteporfin were from Sigma (St. Louis, MO), bortezomib was from Tebu bio (Le Perray en Yvelines, France), bafilomycin A1 and everolimus were from Invivogen (San Diego, CA, USA).

Quinet G., Xolalpa W., Reyes-Garau D., Profitós-Pelejà N., Azkargorta M., Ceccato L., Gonzalez-Santamarta M., Marsal M., Andilla J., Aillet F., Bosch F., Elortza F., Loza-Alvarez P., Sola B., Coux O., Matthiesen R., Roué G, & Rodriguez M.S. (2022). Constitutive Activation of p62/Sequestosome-1-Mediated Proteaphagy Regulates Proteolysis and Impairs Cell Death in Bortezomib-Resistant Mantle Cell Lymphoma. Cancers, 14(4), 923.

+ Open protocol

+ Expand

Multiparametric Flow Cytometry Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used: anti-human CD1a (HI149-APC; BD Pharmigen), CD3 (UCTH1-APC-FIRE750; Biolegend), anti-human CD8a (HIT8a-PerCP-Cy5.5), anti-human CD14 (HCD14-PE-Dazzle594), anti-human CD11c (B-ly6-PE-Cy7), anti-HIV-1 capsid protein p24 (KC57-PE; Beckman Coulter), anti-human LC3 (4E12; MBL Life Science), goat anti-mouse IgG1 (AF488; Invitrogen A-21121).
The following reagents were used: bafilomycin A1 (Invivogen), carbamazepine (Tocris), everolimus (Invivogen), rapamycin (Invivogen), Zidovudine (AZT; NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH), paraformaldehyde (8%, Electron Microscopy Sciences, Aurion), dispase II (Roche Diagnostics), ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich), 2 mM 1,4-dithiothreitol (DTT; Sigma-Aldrich), Collagenase D (Roche), DNAse type I (Worthington Biochemical Corporation).

Cloherty A.P., van Teijlingen N.H., Eisden T.J., van Hamme J.L., Rader A.G., Geijtenbeek T.B., Schreurs R.R, & Ribeiro C.M. (2021). Autophagy-enhancing drugs limit mucosal HIV-1 acquisition and suppress viral replication ex vivo. Scientific Reports, 11, 4767.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!